Aesica successfully introduces serialisation services at Italian finished dose manufacturing and packaging site
The anti-allergy packaging lines actively monitor the integrity and authenticity of products
14th April 2014 - Aesica, the global pharmaceutical contract development and manufacturing organisation (CDMO), has today announced it has successfully introduced serialisation services and initiated commercial production of two anti-allergy product lines for the Chinese market at its Pianezza site, Italy for a global, multinational client. The packaging lines and associated serialisation services are for the dedicated supply for one of Aesica's strategic partners. The implementation took under six months to complete, with the first production of serialisation batches just commenced.
The joint collaboration enabled the skills and unique knowledge of Aesica personnel at Pianezza to deliver serialisation packaging methods and processes that fully comply with stringent State Food and Drug Administration regulations set by the Ministry of Health of China and dovetailed with the partners coding requirements. As a consequence of the partnership, Pianezza is one of the first CDMOs in Italy to have successfully implemented serialisation for a pharmaceutical product.
The serialisation technology uses special digital techniques to check the linear barcode 128 and 20 digit serialised numbers. The code check is in full compliance with international ISO 15416 standards. The check system provides a reliable instrument for checking products and batches all the way through the packaging and distribution process.
The platform has capability for both thermal transfer and thermal ink jet printers for printing stickers with e-codes and variable data with 2D bar codes respectively. High quality variable programming, inks suitable for a multiplicity of applications and ribbons that comply with the latest legislative and environmental standards have all been part of the installation.
Paolo Pizzorni, Senior Director at Aesica Pianezza commented; "We are delighted that our strategic partnership model has seen the successful development of two robust serialisation packaging lines. For our customer this means improved patient safety with a reduced risk of competition from counterfeit products and the ability to detect expired drugs automatically. The end-users are now able to verify the integrity and authenticity of the products dispensed to patients using a simple scan."
He continued: "China is a key geographic market that Western pharma companies seek to export to. At Aesica we are delighted to be providing serialisation services to enable one of our customers to meet the technical and complex serialisation regulations in this market."
Aesica supplies contract development and contract manufacturing services for finished products and active pharmaceutical ingredients to a host of the world's leading pharmaceutical companies and emerging biotechnology organisations.
The uniqueness of Aesica lies in its flexible and bespoke approach to service delivery, coupled with its ability to develop products from the initial clinical stage through to final commercial supply. It is this all-encompassing offering combined with its dedication to exceptional standards of service that truly sets Aesica apart from its counterparts.
· Aesica is one of the UK's fastest growing companiesand over the last five years has more than trebled its turnover.
· The company currently employs approximately 1,300 people.
· In addition to its headquarters in Newcastle upon Tyne, UK, Aesica has development and manufacturing sites across Europe including Cramlington, Nottingham and Queenborough in the UK, as well as sites in Monheim and Zwickau in Germany and Pianezza in Italy.
· The vision of Aesica is to become the number one supplier of APIs and formulated products to the pharmaceutical industry.
· Aesica is a portfolio company of Silverfleet Capital, one of the leading European mid-market private equity firms, which invested in the business in October 2011.
For media enquiries, please contact Tristan Jervis or Alex Heeley on: +44 (0) 207 203 6740 0r e-mail:[email protected].